ArticleScientific reports2021
Elevated plasma miR-133b and miR-221-3p as biomarkers for early Parkinson's disease.
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 2 syntheses or guidelines pooled it, 58 citations in OpenAlex.
- The Role of miRNAs in Parkinson's Disease: A Systematic Review.International journal of molecular sciences · 2025Pooled it
- MicroRNAs in Parkinson's disease: a systematic review and diagnostic accuracy meta-analysis.Scientific reports · 2023Pooled it
- Trial
- Downregulation of miRNAs Accompanies Increased HERV-K (HML-2) Expression in Amyotrophic Lateral Sclerosis.Molecular neurobiology · 2026Article
- Up-regulated miR-4443 Holds Diagnostic Significance for Parkinson's Disease and may be Involved in Neuroinflammation.Molecular neurobiology · 2026Article
- Serum Aberrant Expression of miR-431-5p and Their Diagnostic Value in Parkinson's Disease.Neurochemical research · 2026Article
- miR-133b-3p Mitigates D-Galactose-Induced Hippocampal Neuron Aging Through Autophagy Regulation via the MAPK/ERK Signaling Pathway.Molecular neurobiology · 2025Article
- Review
- Distinct microRNA signatures define sporadic PSP-RS and PD in patient-derived midbrain organoids.iScience · 2025Article
- Epigenetic regulation of iron metabolism and ferroptosis in Parkinson's disease: Identifying novel epigenetic targets.Acta pharmacologica Sinica · 2025Review
- Epigenetic Modulation and Brain Function in Parkinson's Disease: The Role of Exercise Alone or Combined With Polyphenols.Food science & nutrition · 2025Review
- Chronic sleep deprivation induces plasma exosome-derived miR-150-5p downregulation as a novel mechanism involved in Parkinson's disease progression by targeting DCLK1.Journal of translational medicine · 2025Article
- Review
- Unlocking Parkinson's disease: the role of microRNAs in regulation, diagnosis, and therapy.Apoptosis : an international journal on programmed cell death · 2025Review
- RNA dysregulation in neurodegenerative diseases.The EMBO journal · 2025Review
- Mitochondrial micro RNAs: Crucial players in carcinogenesis.Oncology research · 2025Review
- Unraveling the Bone-Brain Axis: A New Frontier in Parkinson's Disease Research.International journal of molecular sciences · 2024Review
- Extracellular Vesicle MicroRNAs as Predictive Biomarkers in Postoperative Delirium After Spine Surgery: Preliminary Study.The journals of gerontology. Series A, Biological sciences and medical sciences · 2024Article
- MicroRNAs regulation in Parkinson's disease, and their potential role as diagnostic and therapeutic targets.NPJ Parkinson's disease · 2024Review
- Dataset of miRNA-disease relations extracted from textual data using transformer-based neural networks.Database : the journal of biological databases and curation · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Blood circulating microRNAs (miRNAs) are proposed to be promising biomarkers for many neurodegenerative disorders, including Parkinson's disease (PD). However, there is a lack of identified differentially expressed miRNAs in PD from different studies. The aim of this study was to evaluate miRNAs expression in PD. We measured plasma circulating miRNA expression in three independent sets with a total of 151 PD patients, 21 multiple system atrophy (MSA) patients and 138 healthy controls using high-throughput RT-PCR. We identified that elevated miR-133b and miR-221-3p discriminated early-stage PD from controls with 94.4% sensitivity and 91.1% specificity. Elevated miR-133b and miR-221-3p distinguished PD from controls with 84.8% sensitivity and 88.9% specificity. In addition, miR-4454 distinguished PD from MSA with 57.1% sensitivity and 82.6% specificity. Hence, elevated miR-133b and miR-221-3p potentially represent good biomarkers for early PD, and a combination of miR-133b, miR-221-3p and miR-4454 has the potential to serve as a non-invasive biomarker for PD diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.